An in vivo study by Zhang et al. showed that FK506-binding protein 12 (FKBP12) ligand co-administered with mTOR inhibitors enabled the retention and brain-specific action of mTOR inhibitors, leading to suppressed tumor growth and improved survival without on-target side effects [65]. Here, FKBP1A is linked to neoplasm.